See more : FTAC Hera Acquisition Corp. (HERA) Income Statement Analysis – Financial Results
Complete financial analysis of Lantern Pharma Inc. (LTRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantern Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- InterMail A/S (IMAIL.CO) Income Statement Analysis – Financial Results
- Jinan High-tech Development Co., Ltd. (600807.SS) Income Statement Analysis – Financial Results
- Sah Polymers Limited (SAH.BO) Income Statement Analysis – Financial Results
- The Rowe Companies, Inc. (ROWC) Income Statement Analysis – Financial Results
- Academy Sports and Outdoors, Inc. (ASO) Income Statement Analysis – Financial Results
Lantern Pharma Inc. (LTRN)
About Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| Gross Profit | -174.84K | -154.68K | -97.42K | -3.39K | -1.63K | 2.54K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.89M | 8.60M | 7.57M | 2.24M | 953.19K | 572.10K |
| General & Administrative | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.98M | 5.83M | 5.02M | 3.66M | 1.48M | 1.15M |
| Other Expenses | 0.00 | -31.55K | 160.55K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Cost & Expenses | 17.88M | 14.43M | 12.59M | 5.91M | 2.43M | 1.73M |
| Interest Income | 765.39K | 204.36K | 67.93K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 204.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 174.84K | 154.68K | 97.42K | 3.39K | 1.63K | -2.54K |
| EBITDA | -15.79M | -14.42M | -12.27M | -5.90M | -2.43M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.88M | -14.43M | -12.59M | -5.91M | -2.43M | -1.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.92M | 172.81K | 228.48K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -15.96M | -14.26M | -12.36M | -5.91M | -2.43M | -1.73M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -172.81K | -67.93K | -202.91K | -5.00 | 2.54K |
| Net Income | -15.96M | -14.09M | -12.30M | -5.91M | -2.43M | -1.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| EPS Diluted | -1.47 | -1.30 | -1.13 | -0.95 | -0.39 | -0.28 |
| Weighted Avg Shares Out | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
| Weighted Avg Shares Out (Dil) | 10.84M | 10.85M | 10.90M | 6.22M | 6.27M | 6.22M |
Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock
Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
Lantern Pharma Secures FDA Orphan Drug Tag For Pancreatic Cancer Candidate
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript
Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
LTRN Stock Increases Over 10% Pre-Market: Why It Happened
Source: https://incomestatements.info
Category: Stock Reports